NASDAQ$HSIC

Henry Schein Inc · Q2 2023 earnings

Q2 2023 earnings · · Investor relations

Briefing

Reported solid results in the second quarter of 2023, driven by North America dental businesses and strength in technology and value-added services.

Henry Schein reported a 2.3% increase in total net sales for Q2 2023, reaching $3.1 billion. GAAP diluted EPS was $1.06, while non-GAAP diluted EPS was $1.31. The company affirms its 2023 non-GAAP diluted EPS guidance of $5.18 to $5.35.

  • Total net sales increased by 2.3% to $3.1 billion compared to Q2 2022.
  • GAAP net income was $140 million, or $1.06 per diluted share.
  • Non-GAAP net income was $173 million, or $1.31 per diluted share.
  • Global Dental sales increased by 5.6% to $2.0 billion, driven by North America.

Headline financials

Total Revenue

$3.1B

Previous: $3.03B+2.3%
EPS (adj)

$1.31

Previous: $1.16+12.9%
Free Cash Flow

$140M

Previous: $160M-12.5%
Net Income

$140M

Previous: $160M-12.5%
Operating Income

$201M

Previous: $220M-8.6%
Gross Profit

$975M

Previous: $945M+3.2%
Cash & Equivalents

$137M

Previous: $108M+26.9%
Total Assets

$9.15B

Previous: $8.32B+9.9%
Stock-Based Comp

$14M

Previous: $15M-6.7%

Revenue & EPS history

Henry Schein · Revenue · Quarterly

$3.1B

Q2 2023+2.3%vs Q2 2022
Beat estimate in 8 of 15 quarters(53%)
ActualEstimate

Revenue by segment

Henry Schein · $2.91B total across 2 segments · Q2 2023

  • Global Dental
    $1.96B+5.6%
  • Global Medical
    $950M-4.6%

Forward guidance

The company expects 2023 sales growth of approximately 1% to 3% over 2022. Sales of PPE products are expected to decrease about 25% to 30%, and COVID-19 test kits are expected to decrease by approximately 70% to 80%.

Headwinds

  • 2023 sales of PPE products are now expected to decrease about 25% to 30%
  • 2023 sales of COVID-19 test kits are now expected to decrease by approximately 70% to 80%
  • 2023 non-GAAP operating margin is expected to be 10 to 15 basis points below 2022 non-GAAP operating margin of 8.2%, largely a result of lower PPE products and COVID-19 test kit sales and profits.
  • The impact on 2023 non-GAAP diluted EPS from lower contributions to earnings from sales of PPE products and COVID-19 test kits is estimated to be $0.35 to $0.40
  • 2023 non-GAAP diluted EPS3:●Remains unchanged at $5.18 to $5.35, which is -4% to -1% compared with 2022 non-GAAP diluted EPS of $5.38

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2023

Historical avgQ2 2023

-0.4%

Avg return

Earnings day

-0.5%

Avg return

5 days after

-0.6%

Avg return

30 days after

45%

31 / 69 earnings

Positive

+11.1%

Q4 2021

Best reaction

-8.5%

Q3 2017

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+3.3%-1.6%+4.6%
Q4 2025+5.8%+2.3%-8.5%
Q3 2025+10.9%+11.2%+13.5%
Q1 2025+2.0%+5.1%+7.8%
Q4 2024-2.3%-7.0%-10.6%
Q3 2024-3.2%-6.0%+0.2%
Q2 2024-5.4%-0.9%+0.4%
Q1 2024+6.2%+7.0%+0.1%
Q4 2023-5.1%-4.6%-6.3%
Q3 2023+7.5%+7.3%+15.5%
Q2 2023-2.8%-1.8%-5.1%
Q1 2023-4.5%-4.2%-6.1%
Q4 2022-6.2%-7.5%-12.8%
Q3 2022+1.8%+6.2%+21.2%
Q2 2022-4.9%-3.8%-7.3%
Q1 2022+7.4%+6.6%+5.6%
Q4 2021+11.1%+10.1%+14.5%
Q3 2021+3.0%+4.5%-6.7%
Q2 2021-4.8%-5.2%-2.3%
Q1 2021+6.6%+8.9%+5.3%
Q4 2020-8.5%-6.5%-5.3%
Q3 2020-5.0%-3.0%+4.6%
Q2 2020-5.3%-4.4%-6.9%
Q1 2020+0.4%+2.9%+20.6%
Q4 2019-8.4%-14.4%-38.9%
Q3 2019+4.4%+4.8%+5.2%
Q2 2019-3.2%-2.3%-4.2%
Q1 2019+8.6%+8.9%+8.6%
Q4 2018-5.0%-5.2%-5.2%
Q3 2018+3.1%+0.8%+3.3%
Q2 2018-0.5%-3.6%+0.5%
Q1 2018-6.1%-4.4%-6.7%
Q4 2017-1.2%-2.1%-5.2%
Q3 2017-8.5%-13.6%-13.0%
Q2 2017-7.7%-7.2%-4.9%
Q1 2017+0.6%+0.3%+5.2%
Q4 2016+2.7%+3.2%+2.0%
Q3 2016+4.6%+6.2%+1.7%
Q2 2016-7.1%-8.4%-8.6%
Q1 2016-2.5%
Q4 2015+7.0%
Q3 2015+1.1%
Q2 2015-1.9%
Q1 2015-0.4%
Q4 2014+0.9%
Q3 2014+5.4%
Q2 2014-1.8%
Q1 2014-1.7%
Q4 2013+0.1%
Q3 2013-2.6%
Q2 2013-0.3%
Q1 2013+2.1%
Q4 2012-2.2%
Q3 2012-0.6%
Q2 2012+1.8%
Q1 2012+2.4%
Q4 2011+3.4%
Q3 2011-6.4%
Q2 2011-2.3%
Q1 2010-2.0%
Q1 2011+0.5%
Q4 2010-3.9%
Q1 2009-3.9%
Q4 2008-3.9%
Q3 2009-4.1%
Q3 2010-4.1%
Q2 2010+2.1%
Q4 2009+2.1%
Q2 2009+2.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro